Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.

On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA System to treat patients with atrial fibrillation, or AFib. The company plans to begin commercial PFA cases in the United States soon and will continue expanding sites across the European Union, following Volt’s CE Mark approval earlier this year.

AFib affects roughly 12 million people in the US over the age of 65, and that number is expected to double over the next 20 years. People living with the condition face a fivefold higher risk of stroke, and AFib has been a contributing cause of death in the United States for more than two decades. When medications and other treatment options fall short, many patients turn to minimally invasive cardiac ablation procedures to stop irregular heart rhythms.

The FDA approval was based on results from Abbott Laboratories (NYSE:ABT)’s VOLT-AF IDE study, which enrolled 392 patients across 40 centers in the United States, Europe, Canada, and Australia. The data showed that the Volt PFA System delivered clinically meaningful safety and effectiveness in two patient groups: people with paroxysmal atrial fibrillation, where episodes come and go, and those with persistent AFib.

Abbott Laboratories (NYSE:ABT) is a global healthcare leader that helps people live more fully at every stage of life. Its portfolio of life-changing technologies spans diagnostics, medical devices, nutritionals, and branded generic medicines.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Cash-Rich Stocks to Buy Now and 15 Global Dividend Stocks to Diversify Your Portfolio.

Disclosure: None.